of the potential use of an existing clinical trial drug to target a specific molecular characteristic possessed by an ovarian cancer include: dasatinib (Sprycel) for Src positive ovarian cancer; [3-5] PARP inhibitors for BRCA gene-mutated (hereditary) ovarian cancer; [6-9] PI3K inhibitors for PIK3CA gene-mutated ovarian cancer; [10] and EC145 for folate-receptor